Abstract:A bispecific antibody (bsAb) is able to bind two different targets or two distinct epitopes on the same target. Broadly speaking, bsAbs can include any single molecule entity containing dual specificities with at least one being antigen-binding antibody domain. Besides additive effect or synergistic effect, the most fascinating applications of bsAbs are to enable novel and often therapeutically important concepts otherwise impossible by using monoclonal antibodies alone or their combination. This so-called obligate bsAbs could open up completely new avenue for developing novel therapeutics. With evolving understanding of structural architecture of various natural or engineered antigen-binding immunoglobulin domains and the connection of different domains of an immunoglobulin molecule, and with greatly improved understanding of molecular mechanisms of many biological processes, the landscape of therapeutic bsAbs has significantly changed in recent years. As of September 2019, over 110 bsAbs are under active clinical development, and near 180 in preclinical development. In this review article, we introduce a system that classifies bsAb formats into 30 categories based on their antigen-binding domains and the presence or absence of Fc domain. We further review the biology applications of approximately 290 bsAbs currently in preclinical and clinical development, with the attempt to illustrate the principle of selecting a bispecific format to meet biology needs and selecting a bispecific molecule as a clinical development candidate by 6 critical criteria. Given the novel mechanisms of many bsAbs, the potential unknown safety risk and risk/benefit should be evaluated carefully during preclinical and clinical development stages. Nevertheless we are optimistic that next decade will witness clinical success of bsAbs or multispecific antibodies employing some novel mechanisms of action and deliver the promise as next wave of antibody-based therapeutics.

Nuclear Imaging of Bispecific Antibodies on the Rise

Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

The present and future of bispecific antibodies for cancer therapy

A pivotal decade for bispecific antibodies?

Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy

Site-specific bioconjugation and nuclear imaging

Bispecific antibodies: advancing precision oncology

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Biology Drives the Discovery of Bispecific Antibodies As Innovative Therapeutics.

Immunotherapeutic progress and application of bispecific antibody in cancer

Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry

State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors

Bispecific Antibodies: From Research to Clinical Application

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Bispecific Antibodies Targeting Immunomodulator Y Checkpoints for Cancer Therapy

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

Bispecific antibodies ( bsAbs ) combine the functionality of two antibodies in one molecule . Two bsAb-drugs

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows